The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation

The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether eltrombopag...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cells
Main Authors: Vogel, Jens-Uwe, Schmidt, Sophie, Schmidt, Daniel, Rothweiler, Florian, Koch, Benjamin, Baer, Patrick, Rabenau, Holger, Michel, Detlef, Stamminger, Thomas, Michaelis, Martin, Cinatl, Jindrich
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7017049/
https://ncbi.nlm.nih.gov/pubmed/31861948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010031
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares